MEA Pharmacogenetics Testing in PsychiatryDepression Market - Industry Trends and Forecast to 2029
- Published Date: 2022-12-22
- Report ID: 143179
- Pages: 225
-
Format:
Short Description
Middle East and Africa Pharmacogenetics Testing in Psychiatry/Depression Market, By Type (Anxiety, Mood Disorders, Depression, Bipolar Disorders, Psychotic Disorders, and Eating Disorders), Test Type (Whole Genome Sequencing, and Chromosomal Array-Based Tests), Patient Type (Childrens, Adults and Geriatric), Gene Type (CYP2C19, CYP2C9, VKORC1, CYP2D6, HLA-B, HTR2A/C, HLA-A, CYP3A4, SLC6A4, MTHFR, COMT, and Others), Products (Instruments, Consumables, and Software & Services), End User (Hospitals and Clinics, Diagnostics Laboratories, Academic and Research Institutes, and Others), Distribution Channel (Direct Tender, Third Party Distribution Hospital Pharmacy, and Others), Countries (UAE, Israel, South Africa, Egypt, Kuwait and Rest of the Middle East and Africa, Brazil, Argentina, Peru, and Rest of South America) - Industry Trends and Forecast to 2029
Market Definition
Pharmacogenomic testing has recently become scalable and available to guide major depressive disorder (MDD). Clinicians increasingly recognize Pharmacogenomic (PGx) testing as an essential tool to guide medication decisions for psychiatric illnesses. Extensive implementation of PGx testing is driving the market in the forecast period.
Pharmacogenetics testing studies the interaction between the drug and the gene response of an individual person and searches for the gene variation, which is responsible for influencing the drug effect. The test is gaining high demand as many researchers and scientists identified the unique interaction between drugs and individual genes and provides valuable insights which subsequently be used to develop customized or personalized medication.
Market Segmentation
The Middle East and Africa pharmacogenetics testing in psychiatry/depression market is categorized into seven notable segments, which are the type, test type, product type, gene type, patient type, end user, and distribution channel.
On the basis of type, the pharmacogenetics testing in psychiatry/depression market is segmented into anxiety, mood disorders, depression, bipolar disorders, psychotic disorders, and eating disorders
On the basis of test type, the pharmacogenetics testing in psychiatry/depression market is segmented into whole genome sequencing, and chromosomal array-based tests
On the basis of patient type, the pharmacogenetics testing in psychiatry/depression market is segmented into children, adults, and geriatrics
On the basis of product type, the pharmacogenetics testing in psychiatry/depression market is segmented into instruments, consumables, and software & services
On the basis of gene type, the pharmacogenetics testing in psychiatry/depression market is segmented into CYP2C19, CYP2C9, VKORC1, CYP2D6, HLA-B, HTR2A/C, HLA-A, CYP3A4, SLC6A4, MTHFR, COMT, and others
On the basis of end user, the pharmacogenetics testing in psychiatry/depression market is segmented into hospitals and clinics, diagnostics laboratories, academic and research institutes, and others
On the basis of distribution channel, the pharmacogenetics testing in psychiatry/depression market is segmented into direct tender, third-party distribution hospital pharmacy, and others
Market Players
Some of the major players operating in the Middle East and Africa pharmacogenetics testing in psychiatry/depression market are:
PacBio
QIAGEN
Thermo Fisher Scientific Inc.
AB BIOTICS.S.A.
Eurofins Scientific
Illumina, Inc.
STADAPHARM GmbH
TABLE OF CONTENTS
1 INTRODUCTION 63
1.1 OBJECTIVES OF THE STUDY 63
1.2 MARKET DEFINITION 63
1.3 OVERVIEW OF MIDDLE EAST & AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET 63
1.4 CURRENCY AND PRICING 65
1.5 LIMITATIONS 66
1.6 MARKETS COVERED 66
2 MARKET SEGMENTATION 70
2.1 MARKETS COVERED 70
2.2 GEOGRAPHICAL SCOPE 71
2.3 YEARS CONSIDERED FOR THE STUDY 72
2.4 DBMR TRIPOD DATA VALIDATION MODEL 73
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 76
2.6 MULTIVARIATE MODELLING 77
2.7 MARKET APPLICATION COVERAGE GRID 78
2.8 SOURCE LIFELINE CURVE 78
2.9 DBMR MARKET POSITION GRID 80
2.10 VENDOR SHARE ANALYSIS 81
2.11 SECONDARY SOURCES 82
2.12 ASSUMPTIONS 82
3 EXECUTIVE SUMMARY 83
3.1 PESTEL ANALYSIS 87
3.2 PORTER'S FIVE FORCES MODEL 88
3.3 INDUSTRIAL INSIGHTS: 89
3.4 PIPELINE ANALYSIS FOR MIDDLE EAST & AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET 91
3.5 EPIDEMIOLOGY 92
4 MIDDLE EAST & AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, REGULATIONS 93
4.1 UNITED STATES (U.S.) 93
4.1.1 ROLE OF FDA 93
4.1.2 ROLE OF CDC AND HCFA 93
4.2 EUROPEAN UNION (EU) 94
4.3 FRANCE 94
4.4 AUSTRALIA 94
4.5 SOUTH KOREA 94
5 MARKET OVERVIEW 95
5.1 DRIVERS 97
5.1.1 INCREASE IN THE NUMBER OF PATIENTS SUFFERING FROM PSYCHIATRIC AND DEPRESSION DISORDER 97
5.1.2 RISE IN HEALTHCARE EXPENDITURE 97
5.1.3 RISE IN DEMAND FOR PERSONALIZED AND PRECISION MEDICINE 98
5.2 RESTRAINTS 98
5.2.1 LACK OF SKILLED MEDICAL AND GENOMIC EXPERT 98
5.2.2 LACK OF STRONG CLINICAL EVIDENCE 99
5.2.3 HIGH COST ASSOCIATED WITH THE DIAGNOSIS 99
5.3 OPPORTUNITIES 99
5.3.1 RISING ADVANCEMENTS IN TECHNOLOGY 99
5.3.2 INCREASING NUMBER OF KEY PLAYERS IN MARKET 100
5.4 CHALLENGES 100
5.4.1 STRICT GOVERNMENT REGULATION ON NEW PRODUCTS AND INSTRUMENTS APPROVAL 100
5.4.2 DEARTH OF SKILLED PERSONNEL 101
6 MIDDLE EAST & AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE 102
6.1 OVERVIEW 103
6.2 ANXIETY 106
6.3 DEPRESSION 106
6.4 MOOD DISORDERS 107
6.5 BIPOLAR DISORDERS 108
6.6 EATING DISORDERS 109
6.7 PSYCHOTIC DISORDERS 109
7 MIDDLE EAST & AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT 111
7.1 OVERVIEW 112
7.2 CONSUMABLES 115
7.2.1 WHOLE GENOME SEQUENCING KITS 116
7.2.2 CHROMOSOMAL ARRAY BASED KITS 116
7.3 INSTRUMENTS 117
7.4 SOFTWARE AND SERVICES 117
8 MIDDLE EAST & AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE 119
8.1 OVERVIEW 120
8.2 WHOLE GENOME SEQUENCING 123
8.2.1 EXOME SEQUENCING 124
8.2.1.1 SNP 125
8.2.1.2 CNV 125
8.2.1.3 RARE PTV MUTATION 125
8.2.1.4 ULTRA PTV MUTATION 125
8.2.1.5 OTHERS 125
8.2.2 KARYOTYPE 125
8.2.2.1 SNP 126
8.2.2.2 CNV 126
8.2.2.3 RARE PTV MUTATION 126
8.2.2.4 ULTRA PTV MUTATION 126
8.2.2.5 OTHERS 126
8.2.3 LOW COVERAGE WGS 126
8.2.3.1 SNP 127
8.2.3.2 CNV 127
8.2.3.3 RARE PTV MUTATION 127
8.2.3.4 ULTRA PTV MUTATION 127
8.2.3.5 OTHERS 127
8.2.4 DEEP COVERAGE WGS 127
8.2.4.1 SNP 128
8.2.4.2 CNV 128
8.2.4.3 RARE PTV MUTATION 128
8.2.4.4 ULTRA PTV MUTATION 128
8.2.4.5 OTHERS 128
8.2.5 MICROARRAY 128
8.2.5.1 SNP 129
8.2.5.2 CNV 129
8.2.5.3 RARE PTV MUTATION 129
8.2.5.4 ULTRA PTV MUTATION 129
8.2.5.5 OTHERS 129
8.2.6 OTHERS 129
8.3 CHROMOSOMAL ARRAY BASED TESTS 129
8.3.1 MICRODELETIONS 130
8.3.2 MICRO DUPLICATIONS 130
9 MIDDLE EAST & AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE TYPE 131
9.1 OVERVIEW 132
9.2 CYP2C19 135
9.3 CYP2C9 AND VKORC1 135
9.4 CYP2D6 136
9.5 HLA-B 137
9.6 HTR2A/C 137
9.7 HLA-A 138
9.8 CYP3A4 139
9.9 SLC6A4 139
9.10 MTHFR 140
9.11 COMT 141
9.12 OTHERS 141
10 MIDDLE EAST & AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE 143
10.1 OVERVIEW 144
10.2 ADULT 147
10.3 GERIATRIC 147
10.4 CHILD 148
11 MIDDLE EAST & AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET , BY END USER 149
11.1 OVERVIEW 150
11.2 HOSPITAL AND CLINICS 153
11.2.1 DRUG EFFECTIVENESS 154
11.2.2 SIDE EFFECTS 154
11.2.3 DOSAGE 154
11.3 DIAGNOSTICS LABORATORIES 154
11.3.1 DRUG EFFECTIVENESS 155
11.3.2 SIDE EFFECTS 155
11.3.3 DOSAGE 155
11.4 ACADEMIC AND RESEARCH INSTITUTES 155
11.4.1 DRUG EFFECTIVENESS 156
11.4.2 SIDE EFFECTS 156
11.4.3 DOSAGE 156
11.5 OTHERS 156
12 MIDDLE EAST & AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL 158
12.1 OVERVIEW 159
12.2 DIRECT TENDER 162
12.3 THIRD PARTY DISTRIBUTION 162
12.4 HOSPITAL PHARMACY 163
12.5 OTHERS 163
13 MIDDLE EAST & AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION 165
13.1 MIDDLE EAST AND AFRICA 166
13.1.1 SOUTH AFRICA 178
13.1.2 SAUDI ARABIA 185
13.1.3 U.A.E 192
13.1.4 ISRAEL 199
13.1.5 EGYPT 206
13.1.6 REST OF MIDDLE EAST AND AFRICA 213
14 MIDDLE EAST & AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET: COMPANY LANDSCAPE 214
14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 214
15 SWOT ANALYSIS 215
16 COMPANY PROFILE 216
16.1 THERMO FISHER SCIENTIFIC INC. 216
16.1.1 COMPANY SNAPSHOT 216
16.1.2 RECENT FINANCIALS 216
16.1.3 COMPANY SHARE ANALYSIS 217
16.1.4 PRODUCT PORTFOLIO 217
16.1.5 RECENT DEVELOPMENT 218
16.2 ILLUMINA, INC. 219
16.2.1 COMPANY SNAPSHOT 219
16.2.2 REVENUE ANALYSIS 219
16.2.3 COMPANY SHARE ANALYSIS 220
16.2.4 PRODUCT PORTFOLIO 220
16.2.5 RECENT DEVELOPMENTS 221
16.3 MYRIAD GENETICS, INC. 223
16.3.1 COMPANY SNAPSHOT 223
16.3.2 COMPANY SHARE ANALYSIS 223
16.3.3 PRODUCT PORTFOLIO 224
16.3.4 RECENT DEVELOPMENT 224
16.4 SONIC HEALTHCARE LIMITED 225
16.4.1 COMPANY SNAPSHOT 225
16.4.2 REVENUE ANALYSIS 225
16.4.3 COMPANY SHARE ANALYSIS 226
16.4.4 PRODUCT PORTFOLIO 226
16.4.5 RECENT DEVELOPMENTS 226
16.5 QIAGEN 227
16.5.1 COMPANY SNAPSHOT 227
16.5.2 RECENT FINANCIALS 227
16.5.3 COMPANY SHARE ANALYSIS 228
16.5.4 PRODUCT PORTFOLIO 228
16.5.5 RECENT DEVELOPMENTS 229
16.6 EUROFINS SCIENTIFIC 230
16.6.1 COMPANY SNAPSHOT 230
16.6.2 REVENUE ANALYSIS 230
16.6.3 PRODUCT PORTFOLIO 231
16.6.4 RECENT DEVELOPMENT 231
16.7 AB-BIOTICS, S.A. 232
16.7.1 COMPANY SNAPSHOT 232
16.7.2 PRODUCT PORTFOLIO 232
16.7.3 RECENT DEVELOPMENTS 232
16.8 BIOGENIQ INC. 234
16.8.1 COMPANY SNAPSHOT 234
16.8.2 PRODUCT PORTFOLIO 234
16.8.3 RECENT DEVELOPMENT 234
16.9 CASTLE BIOSCIENCE, INC. 235
16.9.1 COMPANY SNAPSHOT 235
16.9.2 REVENUE ANALYSIS 235
16.9.3 PRODUCT PORTFOLIO 236
16.9.4 RECENT DEVELOPMENT 236
16.10 CNSDOSE 237
16.10.1 COMPANY SNAPSHOT 237
16.10.2 PRODUCT PORTFOLIO 237
16.10.3 RECENT DEVELOPMENT 237
16.11 COLOR HEALTH, INC. 238
16.11.1 COMPANY SNAPSHOT 238
16.11.2 PRODUCT PORTFOLIO 238
16.11.3 RECENT DEVELOPMENTS 239
16.12 CORIELL LIFE SCIENCES 240
16.12.1 COMPANY SNAPSHOT 240
16.12.2 PRODUCT PORTFOLIO 240
16.12.3 RECENT DEVELOPMENTS 240
16.13 DYNAMIC DNA LABORATORIES 243
16.13.1 COMPANY SNAPSHOT 243
16.13.2 PRODUCT PORTFOLIO 243
16.13.3 RECENT DEVELOPMENTS 243
16.14 GENELEX (SUBSIADIARY OF INVITAE CORPORATION.) 245
16.14.1 COMPANY SNAPSHOT 245
16.14.2 REVENUE ANALYSIS 245
16.14.3 PRODUCT PORTFOLIO 246
16.14.4 RECENT DEVELOPMENT 246
16.15 GENEWIZ (PART OF AZENTA LIFE SCIENCES) 247
16.15.1 COMPANY SNAPSHOT 247
16.15.2 REVENUE ANALYSIS 247
16.15.3 PRODUCT PORTFOLIO 248
16.15.4 RECENT DEVELOPMENTS 248
16.16 GENOMIND, INC. 249
16.16.1 COMPANY SNAPSHOT 249
16.16.2 PRODUCT PORTFOLIO 249
16.16.3 RECENT DEVELOPMENTS 249
16.17 GENXYS 251
16.17.1 COMPANY SNAPSHOT 251
16.17.2 PRODUCT PORTFOLIO 251
16.17.3 RECENT DEVELOPMENTS 251
16.18 HEALTHSPEK 253
16.18.1 COMPANY SNAPSHOT 253
16.18.2 PRODUCT PORTFOLIO 253
16.18.3 RECENT DEVELOPMENTS 253
16.19 HUDSONALPHA 254
16.19.1 COMPANY SNAPSHOT 254
16.19.2 PRODUCT PORTFOLIO 254
16.19.3 RECENT DEVELOPMENT 254
16.20 MD LABS 255
16.20.1 COMPANY SNAPSHOT 255
16.20.2 PRODUCT PORTFOLIO 255
16.20.3 RECENT DEVELOPMENTS 255
16.21 MYDNA LIFE AUSTRALIA PTY LTD. 256
16.21.1 COMPANY SNAPSHOT 256
16.21.2 PRODUCT PORTFOLIO 256
16.21.3 RECENT DEVELOPMENT 256
16.22 ONEOME, LLC 257
16.22.1 COMPANY SNAPSHOT 257
16.22.2 PRODUCT PORTFOLIO 257
16.22.3 RECENT DEVELOPMENTS 257
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
